证券之星消息，根据天眼查APP于2月10日公布的信息整理，上海跃赛生物科技有限公司A++轮融资，融资额5000万人民币，参与投资的机构包括磐霖资本，全村创投，外高桥。 上海跃赛生物科技有限公司(跃赛生物)创立于2021年，是一家专注于开发新一代基于人多能干细胞技术的细胞治疗药物的企业，跃赛生物专注于开发新一代基于人多能干细胞技术的细胞治疗药物，旨在利用人多能干细胞制备、培养、分化和基因编辑技术平台致力于干细胞治疗领域的技术研发和产品开发，其研发管线覆盖神经退行性疾病，罕见病及肿瘤等。数据来源：天眼查APP为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.